Overall, these findings have guided the design and development of several FGF21 analogs and mimetics that have shown promising therapeutic efficacy against obesity and T2D, demonstrating anti-inflammatory, antidiabetic, and hypolipidemic properties [28,49]. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.